m6A-centered Drug Response Information

General Information of the Drug (ID: M6APDG04043)
Name
MTL-CEPBA
Status
Phase 1/2
TTD Drug ID
DA01IB
Target Gene(s) and Their Upstream m6A Regulator, Together with the Effect of Target Gene(s) in Drug Response
The target genes involved in drug-target interaction (such as drug-metabolizing enzymes, drug transporters and therapeutic targets) and drug-mediated cell death signaling (including modulating DNA damage and repair capacity, escaping from drug-induced apoptosis, autophagy, cellular metabolic reprogramming, oncogenic bypass signaling, cell microenvironment, cell stemness, etc.) could be regulated by m6A regulator(s) and affected their corresponding drug response. You can browse detailed information on drug-related target gene(s) mediated by m6A regulators.
CEBPA messenger RNA (CEBPA mRNA)
Fat mass and obesity-associated protein (FTO)
In total 1 mechanisms lead to this potential drug response
 Regulator Info 
Response Summary CEBPA messenger RNA (CEBPA mRNA) is a therapeutic target for MTL-CEPBA. The Fat mass and obesity-associated protein (FTO) has potential in affecting the response of MTL-CEPBA through regulating the expression of CEBPA messenger RNA (CEBPA mRNA). [1], [2]
Methyltransferase-like 14 (METTL14)
In total 1 mechanisms lead to this potential drug response
 Regulator Info 
Response Summary CEBPA messenger RNA (CEBPA mRNA) is a therapeutic target for MTL-CEPBA. The Methyltransferase-like 14 (METTL14) has potential in affecting the response of MTL-CEPBA through regulating the expression of CEBPA messenger RNA (CEBPA mRNA). [2], [3]
References
Ref 1 R-2HG Exhibits Anti-tumor Activity by Targeting FTO/m(6)A/MYC/CEBPA Signaling. Cell. 2018 Jan 11;172(1-2):90-105.e23. doi: 10.1016/j.cell.2017.11.031. Epub 2017 Dec 14.
Ref 2 The selective class I PI3K inhibitor CH5132799 targets human cancers harboring oncogenic PIK3CA mutations. Clin Cancer Res. 2011 May 15;17(10):3272-81. doi: 10.1158/1078-0432.CCR-10-2882. Epub 2011 May 10.
Ref 3 METTL14 Inhibits Hematopoietic Stem/Progenitor Differentiation and Promotes Leukemogenesis via mRNA m(6)A Modification. Cell Stem Cell. 2018 Feb 1;22(2):191-205.e9. doi: 10.1016/j.stem.2017.11.016. Epub 2017 Dec 28.